Payload Information
General Information of This Payload
| Payload ID | PAY0PMPIS |
|||||
|---|---|---|---|---|---|---|
| Name | TLR8 agonist |
|||||
| Synonyms |
TLR8 agonist
Click to Show/Hide
|
|||||
| Target | Toll-like receptor 8 (TLR8) | |||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
SBT6290 [Phase 1/2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients have Nectin-4-expressing advanced/metastatic solid tumors (e.g., urothelial carcinoma, TNBC, NSCLC), measurable disease (RECIST 1.1), ECOG 0-1, and adequate organ function. Exclusions include untreated brain metastases, active autoimmune disease, high-dose steroids (>10mg prednisone/day), uncontrolled ILD, significant ocular disorders, or active HIV/HBV/HCV infections. Archived/accessible tumor tissue for Nectin-4 testing is required.
Click to Show/Hide
|
||||
| Administration Dosage |
Escalating doses by subcutaneous (SC) injection in 21-day cycles
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05234606 | Phase Status | PHASE1|||PHASE2 | ||
| Clinical Description |
A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of SBT6290 Alone and in Combination With PD- (L)1 Inhibitors in Subjects With Advanced Solid Tumors Associated With Nectin-4 Expression
|
||||
| Primary Endpoint |
The primary safety endpoints include dose-limiting toxicities (DLTs) within 28 days post-first SBT6290 dose (Part 1/3) and treatment-emergent adverse events (TEAEs) graded by CTCAE v5.0 across all study parts, monitored until 30 days post-treatment (up to 2 years). Efficacy measures for Part 2/4 include objective response rate (ORR; RECIST 1.1) and duration of response (DOR), tracked until progression/death (up to 3 years).
Click to Show/Hide
|
||||
| Other Endpoint |
Secondary outcomes assess ORR/DOR in Part 1/3, disease control rate (DCR; CR/PR/SD) for ≥6 months, and progression-free survival (PFS; Part 2). Pharmacokinetics (Cmax, AUC) and antidrug antibody (ADA) incidence are evaluated pre-/post-dose for 2 years.
|
||||
References